Exact Sciences
5505 Endeavor Lane
Madison
WI
53719
United States
Tel: 608.284.5700
Website: http://www.exactsciences.com/
Email: jobs@exactsciences.com
519 articles about Exact Sciences
-
Exact Sciences to participate in May 2021 investor conferences
5/3/2021
Exact Sciences Corp. announced that company management will participate in the following conferences and invited investors to participate by webcast.
-
Cologuard® CRC Screening Test Most Cost-Effective Test in Medically Underserved Alaska Native People
4/28/2021
Exact Sciences announces study results published in Mayo Clinic Proceedings showing that Cologuard is the most cost-effective colorectal cancer screening option in the Alaska Native population, as compared to colonoscopy and the fecal immunochemical test, for a wide range of adherence scenarios.
-
Exact Sciences Completes Acquisition of Ashion Analytics, LLC, from The Translational Genomics Research Institute, an affiliate of City of Hope
4/14/2021
Talented team and industry-leading lab will help strengthen the company's sequencing and pipeline capabilities, while broadening its therapy selection and treatment guidance offerings
-
Exact Sciences schedules first quarter 2021 earnings call
4/8/2021
Exact Sciences Corp. announced that the company plans to release its first quarter 2021 financial results after the close of the U.S. financial markets on May 4, 2021.
-
Exact Sciences to participate in March 2021 investor conferences
2/22/2021
Exact Sciences Corp. announced that company management will participate in the following virtual conferences and invited investors to participate by webcast.
-
Exact Sciences Announces Fourth Quarter 2020 Results
2/16/2021
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $466 .3 million for the fourth quarter ended Dec. 31, 2020 and $1,491.4 million for the full year ended Dec. 31, 2020 .
-
Exact Sciences to participate in February 2021 investor conferences
2/1/2021
Exact Sciences Corp. announced that company management will participate in the following conferences and invited investors to participate by webcast.
-
Exact Sciences schedules fourth quarter 2020 earnings call
2/1/2021
Exact Sciences Corp. announced that the company plans to release its fourth quarter 2020 financial results after the close of the U.S. financial markets on February 16, 2021.
-
Exact Sciences Licenses Targeted Digital Sequencing Method to Extend Leadership in Precision Oncology
1/13/2021
Worldwide Exclusive License Provides Access to Targeted Digital Sequencing (TARDIS) Blood Biopsy Method for Use in Minimal Residual Disease Testing
-
New Prospective Data Demonstrate Low False-Positive Rate for Screening Average-Risk People Age 45-49 for Colorectal Cancer with Cologuard®
1/12/2021
Cologuard's high specificity would help minimize risk and cost from unnecessary diagnostic procedures in this age group
-
Exact Sciences Announces Preliminary Fourth Quarter 2020 Results
1/11/2021
Expected total revenue of $464.5-467.5M, including Screening revenue of $249-250M, Precision Oncology revenue of $117-118M, and COVID-19 testing revenue of $98.5-99.5M
-
Exact Sciences to participate in J.P. Morgan Healthcare Conference - Dec 28, 2020
12/28/2020
Exact Sciences Corp. announced that company management will participate in the following conference and invited investors to participate by webcast.
-
Exact Sciences to participate in December 2020 investor conference
11/23/2020
Exact Sciences Corp. announced that company management will participate in the following conference and invited investors to participate by webcast.
-
Leading Diagnostics Companies Join Forces to Establish the Access to Comprehensive Genomic Profiling Coalition (ACGP)
11/17/2020
Consortium aims to make comprehensive genomic profiling accessible to advanced cancer patients in the U.S. to inform medical management and improve patient outcomes.
-
Exact Sciences to participate in November 2020 investor conferences
11/2/2020
Exact Sciences Corp. announced that company management will participate in the following conferences and invited investors to participate by webcast.
-
Exact Sciences Announces Entry into Agreements to Sell $869 Million of Common Stock in Registered Direct Offering
10/27/2020
Exact Sciences Corporation announced the entry into agreements to sell an aggregate of 8,605,483 shares of its common stock, par value $0.01 per share, in a registered direct offering to ten institutional investors, including some of its largest shareholders as well as healthcare specialist firms Casdin Capital and Rock Springs Capital.
-
Exact Sciences To Acquire Thrive Earlier Detection, Becoming A Leader In Blood-Based, Multi-Cancer Screening
10/27/2020
Brings Together Cancer Screening R&D Pioneers to Transform the Future of Cancer Diagnostics and Impact Lives
-
Exact Sciences Announces Third Quarter 2020 Results
10/27/2020
Exact Sciences Corp. announced that the company generated revenue of $408.4 million for the third quarter ended September 30, 2020, compared to $218.8 million for the same period of 2019.
-
The deal, which is worth up to $2.15 billion, is expected to close in the first quarter of 2021 and is subject to regulatory approval.
-
Exact Sciences Selects Veeva Vault Clinical Suite to Help Accelerate Innovation
10/14/2020
Veeva Systems announced that Exact Sciences, a leading provider of cancer screening and diagnostic tests, selected Veeva Vault Clinical Suite to design and run its clinical studies.